Amgen Release: Data Show Efficacy Of Extended Dosing Of Aranesp(R) In The Treatment Of Chemotherapy-Induced Anemia

ORLANDO, Fla.--(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) today announced data from two studies showing that extended dosing of Aranesp® (darbepoetin alfa) is effective in increasing hemoglobin levels to the target level of 11 to 12 g/dL and reducing the need for red blood cell transfusions in patients with chemotherapy-induced anemia. These data were presented at the American Society of Hematology (ASH) 48th Annual Meeting in Orlando, Fla. (Abstracts # 1306, 1552)